Giving patients these two drugs after a heart attack could save thousands of lives

Treating high cholesterol quickly and aggressively after a heart attack may help prevent thousands of new heart attacks and deaths worldwide. Scientists are now urging doctors to rethink the common step-by-step approach to cholesterol treatment and instead start a combination of two medications as early as possible.

When someone has a heart attack, doctors usually start treatment with high-intensity statins right away. These drugs lower "bad" LDL cholesterol, which can stabilize blood vessels and help prevent another heart attack. Clinical trials have shown that using high-intensity statins early after a heart attack leads to fewer cardiovascular problems over time.

Current guidelines recommend starting with statins and adding other drugs only if cholesterol levels stay too high. However, this slow, step-by-step strategy often delays getting cholesterol under control. Studies show fewer than 20% of heart attack patients reach their LDL cholesterol goals with statins alone.

A major problem is that two-thirds of heart attack patients are "statin-naive," meaning they were not on statins when the heart attack happened. For many people, the first time they get any cholesterol-lowering treatment is after their heart event.

Even though high-intensity statins help, the majority still do not reach the recommended target of less than 1.8 mmol/L (70 mg/dL). This leaves patients vulnerable, especially in the first year after a heart attack when the risk of another event is highest.

New research led by Margrét Leósdóttir from Lund University and Kausik Ray from Imperial College London provides strong evidence that an early combination of statins and ezetimibe can change outcomes for the better. Their study used data from 36,000 Swedish heart attack patients collected between 2015 and 2022 through the SWEDEHEART registry.

Rather than relying on a traditional randomized trial, which would be ethically challenging in this case, the researchers used advanced statistical modeling called a "trial emulation clone-censor-weight framework." This method allowed them to closely mimic a real-world clinical trial without putting patients at risk.

The team compared three groups: patients who received ezetimibe within 12 weeks of their heart attack, those who received it later (between 13 weeks and 16 months), and those who never received it.

The results were clear: early combination therapy significantly reduced the risk of new cardiovascular events and death compared to waiting or not adding ezetimibe at all.

If 100% of heart attack patients received early ezetimibe alongside statins, researchers estimate 133 heart attacks could be prevented in a group of 10,000 people over three years. In the UK alone, with around 100,000 heart attacks each year, this could mean preventing 5,000 heart attacks over a decade.

When LDL cholesterol levels stay high after a heart attack, blood vessels remain sensitive and prone to clotting. Lowering cholesterol quickly stabilizes these vessels, cutting the chances of dangerous blockages. Yet many patients never get beyond statin therapy because of delays in follow-up or treatment escalation.

"Today’s guidelines recommend stepwise addition of lipid-lowering treatment. But it’s often the case that this escalation takes too long, it’s ineffective and patients are lost to follow-up," said Margrét Leósdóttir, senior cardiology consultant at Skåne University Hospital.

Ezetimibe, the add-on drug examined in this study, is low-cost, widely available, and causes very few side effects. This makes it an ideal candidate for immediate use after a heart attack. Despite its proven benefits, it is still not routinely given right away in most hospitals.

Professor Kausik Ray emphasized the larger impact: "This study shows that we could save lives and reduce further heart attacks by giving patients a combination of two low-cost drugs. But at the moment patients across the world aren’t receiving these drugs together. That’s causing unnecessary and avoidable heart attacks and deaths—and also places unnecessary costs on healthcare systems."

At Skåne University Hospital, a new treatment algorithm has already been introduced based on these findings. Doctors there now routinely prescribe statins and ezetimibe together immediately after a heart attack. The results have been impressive. Within two months, twice as many patients are reaching their LDL cholesterol targets compared to before the change.

Several other hospitals in Sweden have adopted similar approaches, and early results from those hospitals are just as encouraging.

"My hope is that even more hospitals will review their procedures, so that more patients will get the right treatment in time, and we can thereby prevent unnecessary suffering and save lives," said Dr. Leósdóttir.

The research points to a straightforward solution. Ezetimibe costs about £350 per patient per year in the UK. This is a small price compared to the costs—both human and financial—of treating heart attacks and their long-term effects.

Professor Ray highlighted the economic argument as well: "Our findings suggest that a simple change in treatment guidelines could have a huge impact on patients and reduce the demand on the NHS."

Combination therapy early after a heart attack is not only about saving lives—it’s about using available tools more wisely and efficiently. The evidence is now too strong to ignore. Global health leaders may soon need to revise existing guidelines to reflect this reality.

By treating cholesterol more aggressively right after a heart attack, healthcare providers can give patients the best chance at recovery and help prevent the chain of events that lead to second, third, or even fatal heart attacks.

For patients, this could mean better survival, better quality of life, and a stronger shot at a healthier future.

Research findings are available online in the Journal of the American College of Cardiology.

Note: The article above provided above by The Brighter Side of News.

Like these kind of feel good stories? Get The Brighter Side of News' newsletter.